Search 

Syncona Partners, founded in 2012, is an evergreen investment firm based in London, UK. The firm is an independent subsidiary of the Wellcome Trust who invested the initial £200m capitalization. The firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients, and to hold an ownership position to create value for the Wellcome Trust. The firm is actively screening new investment opportunities.

TEXO Ventures is a healthcare venture capital firm that was founded in 29 and is based in Austin Texas. The firm operates as a hybrid of angel and venture capital. The recent fund closed at $15.4 million in 212. The firm focuses on making equity investments in the Medical Technology and Healthcare IT spaces at near commercialization or early commercialization stage. The firm typically invests ranging from $3 million to $5 million into a company. The firm plans to make 2-3 investments over the next 6-9 month. TEXO Ventures is open to consider companies across the US. The firm primarily focuses on healthcare which includes Health IT Technology  enabled Health Services Chronic Disease Management Managed Care and Benefit Design. Although medical devices and functional diagnostics are considered for investment purposes Texo Ventures must see a clear regulatory pathway and obvious synergies with healthcare reform within a company. The firm's current investment portfolio includes companies in the area of medical technology. Within this field they are in areas such as diagnostic and therapeutic radiation devices electro mechanical medical devices re-usable instruments biomaterials and non-active implantable.

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Further more, the company runs the global Biotech Database (www.biotechgate.com) as a subscription service as well as a white label solution for clients like BIOTECanada, BioCom San Diego, Maryland, HTX, OneNucleus, Swiss Biotech Association, SwedenBIO, Medicon Valley and many more.

Company Valuation:
----------------------------
The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements:

• summary of key risk parameters and strengths of the company
• outline of the crucial factors and value drivers for growth and further strategic development
• assessment of the management, market, science, technology and products
• analysis of the company’s business model and the company’s competitive environment
• detailed calculation of the company’s financial value, using appropriate valuation methods

Product Valuation:
--------------------------
Venture Valuation offers detailed Product Valuation Reports of pre-clinical and clinical products in development that can serve as a basis for negotiations or to structure different deal scenarios. The Product Valuation includes:

• detailed analysis of development costs, time lines, patient population, competing products, pricing and product life cycle
• industry gold standard rNPV valuation methodology based on indication-specific attrition rates and the development stage
• scenario and sensitivity analyses
• analysis of the current value, and forecasts of the future value following the successful completion of key development milestones

As an “add on” module and based on Venture Valuation’s deal database within Biotechgate, benchmarking deals can also be included to provide the client with a differentiated negotiation basis and comparable information.

Licensing Candidate Search:
----------------------------------------
Based on unique valuation and industry expertise, and leveraging access to the proprietary client and products database, Venture Valuation offers individual, tailor-made solutions to customers. The Licensing Candidate Search includes licensing partner identification and an evaluation of potential products for licensing.

Biotechgate Database:
-------------------------------
Venture Valuation has developed and maintains the Biotechgate Database (biotechgate.com). Biotechgate is a global life sciences directory established in 2004 based on the needs of investors and company managers to access accurate and up-to-date industry intelligence.

The database contains over 30’000 company profiles. For Business Development managers, the database provides benchmarking licensing opportunities as well as detailed financial information covering more than 1’600 licensing deals involving therapeutic products and over 5’000 financing rounds.

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.